within Pharmacolibrary.Drugs.ATC.L;

model L01XX27
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.000825,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.042,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.112,
    k12             = 20.4,
    k21             = 20.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX27</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Arsenic trioxide is an antineoplastic agent primarily used in the treatment of acute promyelocytic leukemia (APL) that is refractory to, or has relapsed from, retinoid and anthracycline chemotherapy. It induces apoptosis and partial differentiation of leukemic cells. Arsenic trioxide is approved for use today for specific subtypes of leukemia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients (typical age 27-72) with relapsed or refractory acute promyelocytic leukemia treated with intravenous infusion of arsenic trioxide (0.15 mg/kg) over 1-2 hours.</p><h4>References</h4><ol><li><p>Torka, P, et al., &amp; Griffiths, EA (2016). Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia. <i>Blood reviews</i> 30(3) 201–211. DOI:<a href=&quot;https://doi.org/10.1016/j.blre.2015.11.004&quot;>10.1016/j.blre.2015.11.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26709030/&quot;>https://pubmed.ncbi.nlm.nih.gov/26709030</a></p></li><li><p>Hua, H, et al., &amp; Li, J (2011). Pharmacokinetics of arsenic trioxide (As₂O₃) in Chinese primary hepatocarcinoma patients. <i>Asian Pacific journal of cancer prevention : APJCP</i> 12(1) 61–65. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21517232/&quot;>https://pubmed.ncbi.nlm.nih.gov/21517232</a></p></li><li><p>Gao, C, et al., &amp; Zhou, J (2018). Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. <i>Cancer chemotherapy and pharmacology</i> 82(2) 229–236. DOI:<a href=&quot;https://doi.org/10.1007/s00280-018-3606-8&quot;>10.1007/s00280-018-3606-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29845392/&quot;>https://pubmed.ncbi.nlm.nih.gov/29845392</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX27;
